- Home
- ZEPP vs XGN Comparison
ZEPP vs XGN Comparison
Compare ZEPP & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZEPP | XGN |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.7M | 64.5M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ZEPP | XGN |
|---|---|---|
| Price | $10.86 | $2.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.14 |
| AVG Volume (30 Days) | 106.6K | ★ 295.5K |
| Earning Date | 03-15-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $778.34 | $8.06 |
| Revenue Next Year | N/A | $12.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.13 | $2.63 |
| 52 Week High | $61.50 | $12.23 |
Technical Indicators
Market Signals| Indicator | ZEPP | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 26.08 | 29.26 |
| Support Level | $2.25 | N/A |
| Resistance Level | $15.85 | $3.79 |
| Average True Range (ATR) | 1.66 | 0.20 |
| MACD | -0.53 | -0.00 |
| Stochastic Oscillator | 1.37 | 6.43 |
Price Performance
Historical ComparisonAbout ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.